Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
This study has been completed.
Sponsors and Collaborators: Hospital Universitari Son Dureta
Fondo de Investigación Sanitaria (FIS)
Sociedad Española de Neumología y Cirugía Torácica
Information provided by: Hospital Universitari Son Dureta
ClinicalTrials.gov Identifier: NCT00671151
  Purpose

Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project. NF-kappa B-dependent pathway and acetylation status of nuclear histones are to be studied.Design: controlled, prospective and randomized study with or without theophylline, a potent HDAC activator.Objectives: 1) To determine NF-kB activation, histone deacetylase (HDAC) and histone acetyl-transferase (HAT) activity in sputum macrophages and blood monocytes during an episode of exacerbation and 3 months later, once stability is achieved. To correlate these measurements with inflammatory and oxidative stress markers and with pulmonary function and clinical variables. 2) To assess the effect of theophylline on previous molecular, functional and clinical data. Method: 25 patients with COPD will be recruited during an episode of exacerbation requiring hospitalization. NF-kB activation, HDAC and HAT activity, markers of inflammation and oxidative stress will be determined with specific assays. These determinations will be repeated once the patient is stable and compared with smokers and non smoker controls with normal lung function


Condition Intervention
COPD
Drug: Theophylline

MedlinePlus related topics: COPD (Chronic Obstructive Pulmonary Disease)
Drug Information available for: Theophylline Theophylline sodium glycinate
U.S. FDA Resources
Study Type: Interventional
Study Design: Basic Science, Randomized, Single Blind (Outcomes Assessor), Active Control, Single Group Assignment
Official Title: Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline

Further study details as provided by Hospital Universitari Son Dureta:

Primary Outcome Measures:
  • HDAC activity in alveolar macrophages [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Lung function [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Inflammatory cytokine release in sputum and serum [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 35
Study Start Date: June 2005
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Low-dose theophylline on top of standard therapy for COPD exacerbation
Drug: Theophylline
Theophylline 100 mg bid for 3 months
2: No Intervention
Standard therapy for COPD exacerbation

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Severe COPD according to GOLD guidelines
  • Age between 40 and 75
  • Admission to hospital due to COPD exacerbation

Exclusion Criteria:

  • History of asthma
  • Pulmonary embolism
  • Pneumonia
  • Other chronic inflammatory disease
  • Patient on theophylline at the time of admission
  • Patient on oral steroids at the time of admission
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00671151

Locations
Spain, Baleares
Hospital Universitario Son Dureta
Palma de Mallorca, Baleares, Spain, 07014
Sponsors and Collaborators
Hospital Universitari Son Dureta
Fondo de Investigación Sanitaria (FIS)
Sociedad Española de Neumología y Cirugía Torácica
Investigators
Principal Investigator: Borja G Cosio, MD Hospital Universitario Son Dureta
  More Information

Publications:
Responsible Party: Specialist in Respiratory Medicine ( Borja G Cosio MD )
Study ID Numbers: FIS042146
Study First Received: April 30, 2008
Last Updated: May 2, 2008
ClinicalTrials.gov Identifier: NCT00671151  
Health Authority: Spain: Ethics Committee

Keywords provided by Hospital Universitari Son Dureta:
COPD exacerbation
histone
steroid resistance
inflammation
theophylline

Study placed in the following topic categories:
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases
Theophylline
Inflammation
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:
Respiratory System Agents
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Asthmatic Agents
Enzyme Inhibitors
Cardiovascular Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Bronchodilator Agents

ClinicalTrials.gov processed this record on January 16, 2009